Founded in 2015, MIP Discovery—recently rebranded as Tozaro—uses machine learning and molecular modelling to create proprietary Smart Polymers that replace expensive protein-based reagents in viral-vector production. These synthetic polymers, built from a library of more than 500 chemical groups, bind lentiviral and AAV vectors with higher stability and lower cost than traditional protein or peptide alternatives. The lead programs focus on improving yields and purity for CAR-T lentiviral vectors and broader AAV-based gene therapies, directly addressing one of the largest cost drivers in advanced biologics manufacturing. The platform’s broader ambition is to supply cost-effective chromatography and purification solutions across the biopharmaceutical industry. Headquartered in Bedfordshire, the company employs 28 people. To date, it has raised £23.7 million in venture and angel funding—capital that supports scaling operations and forging commercial partnerships aimed at making gene and cell therapies more financially accessible.

Total raised

$17M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2026